TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trial - Wikidata - awgldk - TriplyDB

TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trial

TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trial

http://www.wikidata.org/entity/Q35105819

about

Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era Interferon-γ and Tumor Necrosis Factor-α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion.

P2860

Q33909086-CF1E1382-1408-46E2-A6A3-13DF9D09F1E3 Q36925103-79D2D870-6D57-4357-9FD3-ABA4B3940687 Q47141309-6F919A85-8A45-4A4D-A2E7-20226CCEC7B5 Q48337458-4CEE9F16-79C5-43F7-9DBE-DA1128DA5165

P2860

TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trial

http://www.wikidata.org/entity/Q35105819

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

TG1042 (Adenovirus-interferon- ...... mas: a phase II clinical trial

@ast

TG1042 (Adenovirus-interferon- ...... mas: a phase II clinical trial

@en

type

label

TG1042 (Adenovirus-interferon- ...... mas: a phase II clinical trial

@ast

TG1042 (Adenovirus-interferon- ...... mas: a phase II clinical trial

@en

prefLabel

TG1042 (Adenovirus-interferon- ...... mas: a phase II clinical trial

@ast

TG1042 (Adenovirus-interferon- ...... mas: a phase II clinical trial

@en

P1433

Q35105819-0A608D31-E117-441D-AC02-08A1DA51DC9F

P1476

Q35105819-61843F04-7E08-4EF7-8EF6-A5DC64EDAC00

P2093

Q35105819-0DDC631C-20D2-4EB2-9293-51A5C93D42A3

Q35105819-1E53A4B2-2CE6-4386-9C00-773F4E5A2370

Q35105819-33FA2D17-71F8-40DD-9DDE-9E91FF545528

Q35105819-36CD2D46-0A22-42A8-AEAF-2D5F6AAB731D

Q35105819-44A2D96B-8FF4-4F5E-872A-052AD39D2580

Q35105819-511C050C-C01F-4F01-A457-B587132B37B9

Q35105819-54E5C5E6-B594-4405-A7B8-3FB1FB9C0B03

Q35105819-5A7AB4AE-385B-4461-B58D-6CD4A30CB6FB

Q35105819-682507B8-242A-444E-8313-A0B2FDC53229

Q35105819-73D56CDD-8074-43EC-B95F-497F6024AF3A

P2860

Q35105819-060CD8FE-CF1E-4B2B-AFCD-01AC83EBE876

Q35105819-1B6EE442-8CE0-44C1-8531-204660F2C98F

Q35105819-21F4DA49-125D-46D4-8727-63A5A682043B

Q35105819-2F8EBCA8-AA26-4526-B41D-C510525B523B

Q35105819-35F6BB9E-58F3-4FD8-9553-E66B33B731A7

Q35105819-3C7534BB-2F87-4F3A-B66B-99D64B2AD599

Q35105819-4510DC11-94A5-441C-8F3F-A61B047BA71F

Q35105819-4E75829C-9044-448F-A30E-A7B251730118

Q35105819-5E0A9BA5-A847-4D9C-8A9C-BF19E3D12F00

Q35105819-883C4F4D-1832-42C6-AA55-B56DCA0AB295

P304

Q35105819-C1DC4DFA-A168-4973-BFDB-1F348B9C8A71

P31

Q35105819-4E65E4F1-8ABB-4147-A498-50C0E3C066B0

P356

Q35105819-0EFE9D35-8B06-42AC-9679-6ABC40BB45DE

P433

Q35105819-D5D0BBB7-6758-4F17-AE53-B14B2DE8BB7C

P478

Q35105819-976E5A0F-C0AF-4F19-A87F-42BBE3508A62

P577

Q35105819-30E38CD3-9076-4F9B-8DA6-626B6C3CCB75

P5875

Q35105819-AADD0612-124E-4534-8E19-E6DF63946A61

P698

Q35105819-DAF46243-FA65-4B29-87B8-1DC0BAE3AEDA

P921

Q35105819-5D4CFBD7-5513-4E98-9966-4D47CCB4BF58

Q35105819-5EF9B278-B96E-4DB6-BDC6-49E1E3BBB0FE

P932

Q35105819-C4C3AA9A-97F0-4F90-8E77-B8C6B641EF73

P356

JOURNAL.PONE.0083670

P1433

P1476

TG1042 (Adenovirus-interferon- ...... mas: a phase II clinical trial

@en

P2093

Amir Khammari

http://www.w3.org/2001/XMLSchema#string

Anna Derbij

http://www.w3.org/2001/XMLSchema#string

Anne-Chantal Knol

http://www.w3.org/2001/XMLSchema#string

Anne-Marie Santoni

http://www.w3.org/2001/XMLSchema#string

Brigitte Dreno

http://www.w3.org/2001/XMLSchema#string

Bruce Acres

http://www.w3.org/2001/XMLSchema#string

Isabelle Didillon

http://www.w3.org/2001/XMLSchema#string

Jean-Marc Limacher

http://www.w3.org/2001/XMLSchema#string

Joan Guitart

http://www.w3.org/2001/XMLSchema#string

Madeleine Duvic

http://www.w3.org/2001/XMLSchema#string

P2860

Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas.

Pathogenesis of cutaneous lymphomas.

WHO-EORTC classification for cutaneous lymphomas.

European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas.

Interferon in the treatment of cutaneous T-cell lymphoma.

10 years experience of the Dermatology Life Quality Index (DLQI).

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases.

Primary cutaneous lymphomas: a reprisal.

P304

e83670

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0083670

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260447557

http://www.w3.org/2001/XMLSchema#string

P698

24586226

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3933342

http://www.w3.org/2001/XMLSchema#string